Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Characterisation of sediments during transport of solids in circular sewer pipes.

Regueiro-Picallo M, Anta J, Suárez J, Puertas J, Jácome A, Naves J.

Water Sci Technol. 2017 Apr;2017(1):8-15. doi: 10.2166/wst.2018.055.

PMID:
29698216
2.

Experimental study of pollutant washoff on a full-scale street section physical model.

Naves J, Jikia Z, Anta J, Puertas J, Suárez J, Regueiro-Picallo M.

Water Sci Technol. 2017 Nov;76(9-10):2821-2829. doi: 10.2166/wst.2017.345.

PMID:
29168722
3.

Monitoring accumulation sediment characteristics in full scale sewer physical model with urban wastewater.

Regueiro-Picallo M, Naves J, Anta J, Suárez J, Puertas J.

Water Sci Technol. 2017 Jul;76(1-2):115-123. doi: 10.2166/wst.2017.118.

PMID:
28708616
4.

A Bayesian cost-effectiveness analysis of a telemedicine-based strategy for the management of sleep apnoea: a multicentre randomised controlled trial.

Isetta V, Negrín MA, Monasterio C, Masa JF, Feu N, Álvarez A, Campos-Rodriguez F, Ruiz C, Abad J, Vázquez-Polo FJ, Farré R, Galdeano M, Lloberes P, Embid C, de la Peña M, Puertas J, Dalmases M, Salord N, Corral J, Jurado B, León C, Egea C, Muñoz A, Parra O, Cambrodi R, Martel-Escobar M, Arqué M, Montserrat JM; SPANISH SLEEP NETWORK.

Thorax. 2015 Nov;70(11):1054-61. doi: 10.1136/thoraxjnl-2015-207032. Epub 2015 Aug 26.

5.

Osteopathic manipulative therapy induces early plasma cytokine release and mobilization of a population of blood dendritic cells.

Walkowski S, Singh M, Puertas J, Pate M, Goodrum K, Benencia F.

PLoS One. 2014 Mar 10;9(3):e90132. doi: 10.1371/journal.pone.0090132. eCollection 2014.

6.

Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice.

Krzemieniecki K, Sevelda P, Erdkamp F, Smakal M, Schwenkglenks M, Puertas J, Trojan A, Szabo Z, Bendall K, Maenpaa J.

Support Care Cancer. 2014 Mar;22(3):667-77. doi: 10.1007/s00520-013-2021-2. Epub 2013 Oct 24.

7.

Clinical profile of Spanish postmenopausal women with a diagnosis of osteoporosis and risk factors for endometrial pathology, breast cancer, and cardiovascular disease.

Palacios S, Neyro JL, Puertas JC, Fernandez de Cabo S.

Menopause. 2013 Aug;20(8):852-9. doi: 10.1097/GME.0b013e318280a2f6.

PMID:
23481116
8.

PPCPs wet weather mobilization in a combined sewer in NW Spain.

Del Río H, Suárez J, Puertas J, Ures P.

Sci Total Environ. 2013 Apr 1;449:189-98. doi: 10.1016/j.scitotenv.2013.01.049. Epub 2013 Feb 17.

PMID:
23425796
9.

RS3PE syndrome as a first manifestation of bladder carcinoma.

Bruscas Izu C, Puertas JR, Cabrerizo-García JL.

Reumatol Clin. 2013 Jan-Feb;9(1):74. doi: 10.1016/j.reuma.2012.07.003. Epub 2012 Nov 24. English, Spanish. No abstract available.

10.

Expression of metallocarboxypeptidase inhibitors in Escherichia coli: effect of cysteine content and protein size in the secretory production of disulfide-bridged proteins.

Puertas JM, Caminal G, González G.

J Ind Microbiol Biotechnol. 2011 Sep;38(9):1553-60. doi: 10.1007/s10295-011-0944-5. Epub 2011 Feb 8.

PMID:
21301927
11.

Overland flow computations in urban and industrial catchments from direct precipitation data using a two-dimensional shallow water model.

Cea L, Garrido M, Puertas J, Jácome A, Del Río H, Suárez J.

Water Sci Technol. 2010;62(9):1998-2008. doi: 10.2166/wst.2010.746.

PMID:
21045324
12.

Enhancing the secretory yields of leech carboxypeptidase inhibitor in Escherichia coli: influence of trigger factor and signal recognition particle.

Puertas JM, Nannenga BL, Dornfeld KT, Betton JM, Baneyx F.

Protein Expr Purif. 2010 Nov;74(1):122-8. doi: 10.1016/j.pep.2010.06.008. Epub 2010 Jun 22.

PMID:
20600941
13.

Engineering an efficient secretion of leech carboxypeptidase inhibitor in Escherichia coli.

Puertas JM, Betton JM.

Microb Cell Fact. 2009 Oct 29;8:57. doi: 10.1186/1475-2859-8-57.

14.

Heart metastases and superior vena cava syndrome.

Rubiales AS, Reyes A, Renedo AF, Torrego JC, Puertas J, Marcos G.

Clin Transl Oncol. 2007 Aug;9(8):540-2.

PMID:
17720658
15.

High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: a Phase II multicentric trial.

Pérez-Gracia JL, Colomer R, Esteban E, Barceló R, Benavides M, Puertas J, Arcediano A, Tornamira MV, Valentín V, Muñoz A, Cortés-Funes H, Hornedo J.

Cancer. 2001 Nov 15;92(10):2508-16.

PMID:
11745183
16.

A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer.

Esteban E, de Sande G, Puertas J, Fra J, Palacio I, Vieitez JM, Fernández JL, Muñiz I, Modollel A, Carrasco J, Sala M, Lacave AJ.

Breast Cancer Res Treat. 2000 Jul;62(2):127-33.

PMID:
11016750
17.

[Hormone of the circulatory system; padutine].

APARICIO L, GALLEGO A, PUERTAS JF.

Arch Inst Farmacol Exp (Madr). 1953;5(1-2):38-46. Undetermined Language. No abstract available.

PMID:
13181685

Supplemental Content

Loading ...
Support Center